Europe Biopharmaceutical Contract Manufacturing Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product (Biologics and Biosimilar), Service (Process Development, Fill and Finish Operation, Analytical and QC Studies, and Packaging), and

Europe Biopharmaceutical Contract Manufacturing Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product (Biologics and Biosimilar), Service (Process Development, Fill and Finish Operation, Analytical and QC Studies, and Packaging), and Source (Mammalian and Microbial-Based Biologics/Non-Mammalian)

The biopharmaceutical contract manufacturing market in Europe is expected to grow from US$ 4,610.37 million in 2021 to US$ 8,026.13 million by 2028; it is estimated to register a CAGR of 8.2% from 2021 to 2028.

The contract manufacturing market for biologics is growing at an unprecedented rate due to increasing biologics pipeline, manufacturing complexity, and companies shifting their focus toward core activities. Many pharmaceutical & biotechnology companies outsource varied services, such as early-stage drug development and commercial-scale manufacturing. Outsourcing is required to expedite research & development, speed up market entry, give access to novel technologies, provide regulatory expertise, and reduce risks at a competitive cost. Complexities in biologics development & production and increasingly stringent quality standards have driven drug manufacturers to prefer contract manufacturer services. The demand for contract manufacturing of biologics increased due to difficulties faced in producing large-scale biologics in-house. The production will increase after the approval of novel technologies, such as manufacturing CAR-T therapy. With more biological products and biosimilars entering the market, the competition is rising within the biopharmaceutical sector. Biologics manufacturers strive to reduce manufacturing costs, deliver high-quality drugs, improve process efficiency, and accelerate market entry. CMOs can adopt as per requirements and help in the innovation process and improve operational efficiency. As the pharmaceutical industry is shifting from large-scale production to niche and targeted therapies (personalized medicine), the demand for flexible operational capabilities, production scales, and multiple-product operations are offering significant advantages to contract manufacturing organizations (CMOs). Moreover, many companies are opting for CMOs services to speed up the development process and lower production costs, leading to the biopharmaceutical contract manufacturing market growth.

Europe Biopharmaceutical Contract Manufacturing Market Revenue and Forecast to 2028 (US$ Million)

Europe Biopharmaceutical Contract Manufacturing Market Segmentation

Europe Biopharmaceutical Contract Manufacturing Market – By Product

Biologics Monoclonal Antibodies Recombinant Proteins Vaccines Others Biosimilar

Europe Biopharmaceutical Contract Manufacturing Market – By Service

Process Development Downstream Processing Upstream Processing Fill and Finish Operation Analytical and QC Studies Packaging

Europe Biopharmaceutical Contract Manufacturing Market – By Source

Mammalian Microbial-Based Biologics/ Non-Mammalian

Europe Biopharmaceutical Contract Manufacturing Market– By Country

Germany France The UKItaly Spain The Rest of Europe Europe Biopharmaceutical Contract Manufacturing Market-Companies Mentioned

Abb Vie Inc.Ajinomoto Co. Inc Boehringer Ingelheim International Gmb H General Electric Company Lonza MERCK KGAASamsung Biologics THERMO FISHER SCIENTIFIC INCWUXI BIOLOGICS

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Europe Biopharmaceutical Contract Manufacturing Market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the Europe Biopharmaceutical Contract Manufacturing Market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the Biopharmaceutical Contract Manufacturing Market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution